治疗慢性乙型肝炎的新型反义寡核苷酸药物——bepirovirsen

A novel antisense oligonucleotide drug for the treatment of chronic hepatitis B: bepirovirsen

bepirovirsen(研发代号:IONIS HBVRx、GSK3228836)是一款由伊奥尼斯制药公司和葛兰素史克公司共同研发的反义寡核苷酸(ASO),用于治疗慢性乙型肝炎(CHB)。CHB是全球关注的公共卫生问题,其致病病原体为乙型肝炎病毒(HBV)。bepirovirsen具有抑制HBV复制,同时促进人体自身免疫清除HBV的双重功能。目前已进入Ⅲ期临床研究阶段,已公布的临床研究结果显示,bepirovirsen可持续清除HBsAg和HBVDNA。该药物将为CHB患者带来新的治疗方案,有望功能性治愈CHB。本文就bepirovirsen的基本信息、作用机制、临床前研究及临床研究等作简要概述。

Bepirovirsen(research code:IONIS HBVRx,GSK3228836)is an antisense oligonucleotides(ASO)jointly developed by Ionis Pharmaceuticals and GSK Biologicals,for the treatment of chronic hepatitis B(CHB).CHB is a global public health concern caused by the pathogen hepatitis B virus(HBV).Bepirovirsen has the dual function of inhibiting HBV replication and promoting the body´s autoimmune clearance of HBV.Currently,it has entered the phaseⅢclinical study stage,and published clinical study results show that bepirovirsen can continuously clear HBsAg and HBV-DNA.The drug will lead to a new treatment option for patients with CHB,which is expected to functionally cure CHB.The review provides a brief overview of the basic information,mechanism of action,preclinical research and clinical research of bepirovirsen.